Overview
CLOV market data
Price History
CLOV price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.52 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.58 – $5.59 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.4B · P/B 4.63 · P/S 1.09.
Company News
UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5Benzinga · Aug 6, 2026, 7:04 PM
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On ThursdayBenzinga · Aug 6, 2026, 2:01 PM
Clover Health Investments shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.Benzinga · Aug 6, 2026, 11:50 AM
Clover Health Investments Raises FY2026 Sales Guidance from $2.810B-$2.920B to $2.920B-$3.000B vs $2.910B EstBenzinga · Aug 5, 2026, 8:30 PM
Clover Health Investments Q2 EPS $0.05 Beats $0.03 Estimate, Sales $743.167M Beat $728.267M EstimateBenzinga · Aug 5, 2026, 8:14 PM
Clover Health's CEO Just Sold 62,711 Shares for Tax Withholding. The Bigger News Comes Next Week.The Motley Fool · Jul 31, 2026, 1:31 PM
'Trump Administration To End Medicare Drug Plan Subsidy; Program That Held Down Premiums Not Renewed For 2027, Resulting In Higher Costs For Some Seniors' - WSJ ExclusiveBenzinga · Jul 28, 2026, 8:02 PM
Clover Health Investments shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $4.2 to $5.5.Benzinga · Jul 21, 2026, 2:25 PM
Canaccord Genuity Maintains Buy on Clover Health Investments, Raises Price Target to $5.5Benzinga · Jul 21, 2026, 11:19 AM
Clover Health Investments Reports Anomalous Login Activity On Information Systems On July 4, 2026; Does Not Expect Material Impact From Incident; Threat Actor Accessed Three Non-Managerial Employee Accounts Via Social Engineering; Accessed Accounts Had Member Data But No Access To Financial Or Claims Systems; Co. Believes Unauthorized Access Was Contained And TerminatedBenzinga · Jul 17, 2026, 8:35 PM